LONDON (Alliance News) - GlaxoSmithKline PLC on Friday said it has received a positive opinion from European regulators on plans to expand the current therapeutic indication for its Volibris drug to be used in combination treatment for patients with pulmonary arterial hypertension.
Glaxo said the positive opinion had been given by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
A study recently conducted by Glaxo found a combination of Volibris, or ambrisentan, with tadalafil reduced the risk of clinical failure by 50% in patients compared the results for monotherapy using either drug.
Shares in Glaxo were up 1.9% to 1,362.00 pence on Friday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)